The National Health Surveillance Agency (Anvisa) reported that, on Monday, 28, a meeting was held with technicians from the agency and the Butantan Institute to discuss the Butanvac vaccine against covid-19. According to the agency, the clinical research protocol is already approved, but there is still a lack of specific data to start the tests in humans.
In a note, the regulatory body states that the purpose of the meeting was to evaluate the information already presented by Butantan. “But for the vaccine to start being applied to human beings, it is necessary to present specific data, which are still being generated by Butantan”, he says. According to Anvisa, an example of the missing data refers to the inactivation of the virus used in the vaccine.
Read Also
- Pfizer vaccine, sources: Ema will evaluate if there are data for full ok Aug 31, 2021
- Brazil registers 21,804 new cases of Covid and 692 deaths from the disease – ISTOÉ DINHEIRO Sep 4, 2021
- In China figured out how long immunity recover from coronavirus Jun 20, 2020
- Pfizer vaccine, “effective in the age group 5-11 years at lower doses” Sep 20, 2021
- Chile turns the page on the second wave of coronavirus with benefits for those vaccinated Jul 15, 2021
- The race to the pill against covid proceeds in slow motion, but … Apr 19, 2021
- Fear of malaria variant that is resistant to drugs … Apr 15, 2021